Patent application EP16020193A (EP), filed 2016-05-27
Publication number: EP3225253A1
Title: CANCER THERAPY WITH AN ONCOLYTIC VIRUS COMBINED WITH A CHECKPOINT INHIBITOR
Abstract: [0001]    The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.
IPC codes: A61K  35/   768            A I
A61K  39/    00            A I
A61K  39/   395            A I
Claims: number: 1
text: Pharmaceutical composition containing (a) an oncolytic virus in combination with (b) a checkpoint inhibitor.
number: 2
text: The pharmaceutical composition of claim 1, wherein the oncolytic virus is parvovirus H-1 or a related rodent parvovirus selected from LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), or Rat virus (RV).
number: 3
text: The pharmaceutical composition of claim 1, wherein the checkpoint inhibitor is an anti-PD1 antibody.
number: 4
text: The pharmaceutical composition of claim 3, wherein the anti-PD1-antibody is pembrolizumab.
number: 5
text: The pharmaceutical composition of any of claims 1-4, further comprising one or more additional therapeutic agents selected from chemotherapeutic agents, biotherapeutic agents, an immunogenic agents, immune stimulating cytokines and cells transfected with genes encoding immune stimulating cytokines.
number: 6
text: The pharmaceutical composition as defined in any of claims 1-5 for use in a method of treating cancer.
number: 7
text: The pharmaceutical composition for the use according to claim 6, wherein the oncolytic virus and the checkpoint inhibitor are sequentially administered.
number: 8
text: The pharmaceutical composition for the use according to claim 6 or 7, wherein the use is for treating solid tumours, haematological cancer and/or cancer initiating stem cells.
number: 9
text: The pharmaceutical composition for use according to any of claims 6 to 8, wherein the cancer is brain cancer, colon cancer, bladder cancer, liver cancer, breast cancer kidney cancer, head/neck squamous cell carcinoma, lung cancer, malignant melanoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer or stomach cancer.
number: 10
text: The pharmaceutical composition for the use according to any of claim 9, wherein the brain cancer is glioblastoma multiforme.
number: 11
text: The pharmaceutical composition for the use according to any one of claims 6 to 10, wherein the oncolytic virus and/or the checkpoint inhibitor are administered by intratumoral or intravenous administration.
number: 12
text: A kit which comprises a first container, a second container and a package insert, wherein the first container comprises at least one dose of a pharmaceutical composition containing an oncolytic virus, the second container comprises at least one dose of a pharmaceutical composition comprising a checkpoint inhibitor, and the package insert comprises instructions for treating an individual having cancer using the pharmaceutical composition(s).
number: 13
text: The kit of claim 12, wherein the cancer is brain cancer, colon cancer, bladder cancer, liver cancer, breast cancer kidney cancer, head/neck squamous cell carcinoma, lung cancer, malignant melanoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer or stomach cancer.
number: 14
text: The kit of claim 13, wherein the brain cancer is glioblastoma multiforme.
Office action: search_report, dated 2017-10-04
Rejection reasons: novelty_epc_54
inventive_step_epc_56
Prior art cited: ref_id: WO2009083232A1
ref_type: patent
severity: background
ref_id: WO2011113600A1
ref_type: patent
severity: background
ref_id: US8217149B2
ref_type: patent
severity: background
ref_id: US201213511538A
ref_type: patent
severity: background
ref_id: US201213478511A
ref_type: patent
severity: background
ref_id: US7521051B2
ref_type: patent
severity: background
ref_id: US8008449B2
ref_type: patent
severity: background
ref_id: US8354509B2
ref_type: patent
severity: background
ref_id: WO2008156712A1
ref_type: patent
severity: background
ref_id: - PARDOLL, D., NATURE REVIEWS CANCER, vol. 12, 2012, pages 252 - 264
ref_type: npl
severity: background
ref_id: - WHO DRUG INFORMATION, vol. 27, no. 2, 2013, pages 161 - 162
ref_type: npl
severity: background
ref_id: - WHO DRUG INFORMATION, vol. 27, no. 1, 2013, pages 68 - 69
ref_type: npl
severity: background
ref_id: - WAWRZYNCZAK: "Antibody Therapy", 1996, BIOS SCIENTIFIC PUB. LTD.
ref_type: npl
severity: background
ref_id: - KRESINA: "Monoclonal Antibodies, Cytokines and Arthritis", 1991, MARCEL DEKKER
ref_type: npl
severity: background
ref_id: - BACH: "Monoclonal Antibodies and Peptide Therapy in Autoimmune Diseases", MARCEK DEKKER
ref_type: npl
severity: background
ref_id: - BEART ET AL., NEW ENGL. J. MED., vol. 348, 2003, pages 601 - 608
ref_type: npl
severity: background
ref_id: - MILGROM ET AL., NEW ENGL.J. MED, vol. 341, 1999, pages 1966 - 1973
ref_type: npl
severity: background
ref_id: - SLAMON ET AL., NEW ENGL. J. MED, vol. 344, 2001, pages 783 - 792
ref_type: npl
severity: background
ref_id: - BENIAMINOVITZ, NEW ENGL. J. MED., vol. 342, 2000, pages 613 - 619
ref_type: npl
severity: background
ref_id: - GHOSH ET AL., NEW ENGL. J. MED., vol. 348, 2003, pages 24 - 32
ref_type: npl
severity: background
ref_id: - LIPSKY ET AL., NEW ENGL. J. MED, vol. 343, 2000, pages 1594 - 1602
ref_type: npl
severity: background
ref_id: - "Physicians' Desk Reference (Pdr), 57th edition", November 2002, THOMSON P D R, ISBN: 1563634457
ref_type: npl
severity: background
ref_id: - SILAHTAROGLU ET AL., MOLECULAR AND CELLULAR PROBES, vol. 17, 2003, pages 165 - 169
ref_type: npl
severity: background
ref_id: - NEHME ET AL., J NEUROSCI METHODS, vol. 196, 2011, pages 281 - 288
ref_type: npl
severity: background
ref_id: - BREITBACH CJ; BURKE J; JONKER D; STEPHENSON J; HAAS AR; CHOW LQ; NIEVA J; HWANG TH; MOON A; PATT R ET AL.: "Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans", NATURE, vol. 477, 2011, pages 99 - 102
ref_type: npl
severity: background
ref_id: - CASTRO, F.; DIRKS, W.G.; FAHNRICH, S.; HOTZ-WAGENBLATT, A.; PAWLITA, M.; SCHMITT, M.: "High-throughput SNP-based authentication of human cell lines", INT J CANCER, vol. 132, 2013, pages 308 - 314
ref_type: npl
severity: background
ref_id: - COTMORE SF; TATTERSALL P: "Parvoviral host range and cell entry mechanisms", ADV VIRUS RES, vol. 70, 2007, pages 183 - 232
ref_type: npl
severity: background
ref_id: - DI PIAZZA M; MADER C; GELETNEKY K; HERRERO Y CALLE M; WEBER E; SCHLEHOFER J; DELEU L; ROMMELAERE J: "Cytosolic Activation of Cathepsins Mediates Parvovirus H-1-Induced Killing of Cisplatin and TRAIL-Resistant Glioma Cells", JOURNAL OF VIROLOGY, vol. 81, 2007, pages 4186 - 4198, XP002483096, DOI: doi:10.1128/JVI.02601-06
ref_type: npl
severity: background
ref_id: - GELETNEKY K; HUESING J; ROMMELAERE J; SCHLEHOFER JR; LEUCHS B; DAHM M; KREBS O; VON KNEBEL DOEBERITZ M; HUBER B; HAJDA J: "Phase I/Ila study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.", BMC CANCER, vol. 12, 2012, pages 99, XP021132689, DOI: doi:10.1186/1471-2407-12-99
ref_type: npl
severity: background
ref_id: - FRIDMAN, W.H.; PAGES, F.; SAUTES-FRIDMAN, C.; GALON, J.: "The immune contexture in human tumours: impact on clinical outcome", NAT REV CANCER, vol. 12, 2012, pages 298 - 306, XP055023841, DOI: doi:10.1038/nrc3245
ref_type: npl
severity: background
ref_id: - GABRILOVICH, D.I.; OSTRAND-ROSENBERG, S.; BRONTE, V.: "Coordinated regulation of myeloid cells by tumours", NAT REV IMMUNOL, vol. 12, 2012, pages 253 - 268
ref_type: npl
severity: background
ref_id: - HALAMA, N.; BRAUN, M.; KAHLERT, C.; SPILLE, A.; QUACK, C.; RAHBARI, N.; KOCH, M.; WEITZ, J.; KLOOR, M.; ZOERNIG, I. ET AL.: "Natural Killer Cells are Scarce in Colorectal Carcinoma Tissue Despite High Levels of Chemokines and Cytokines", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 17, 2011, pages 678 - 689
ref_type: npl
severity: background
ref_id: - HALAMA, N.; MICHEL, S.; KLOOR, M.; ZOERNIG, I.; BENNER, A.; SPILLE, A.; POMMERENCKE, T.; VON, K.N.E.B.E.I.D.M.; FOLPRECHT, G.; LUB: "Localization and Density of Immune Cells in the Invasive Margin of Human Colorectal Cancer Liver Metastases Are Prognostic for Response to Chemotherapy.", CANCER RES, vol. 71, 2011, pages 5670 - 5677, XP055015732, DOI: doi:10.1158/0008-5472.CAN-11-0268
ref_type: npl
severity: background
ref_id: - HALAMA, N.; MICHEL, S.; KLOOR, M.; ZOERNIG, I.; POMMERENCKE, T.; VON KNEBEL DOEBERITZ, M.; SCHIRMACHER, P.; WEITZ, J.; GRABE, N.;: "The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy", CANCER IMMUNITY, vol. 9, 2009, pages 1
ref_type: npl
severity: background
ref_id: - HALAMA, N.; SPILLE, A.; LERCHL, T.; BRAND, K.; HERPEL, E.; WELTE, S.; KEIM, S.; LAHRMANN, B.; KLUPP, F.; KAHLERT, C. ET AL.: "Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration.", ONCOIMMUNOLOGY, vol. 2, 2013, pages E24116
ref_type: npl
severity: background
ref_id: - HALAMA, N.; ZOERNIG, I.; SPILLE, A.; MICHEL, S.; KLOOR, M.; GRAULING-HALAMA, S.; WESTPHAL, K.; SCHIRMACHER, P.; JAEGER, D.; GRABE,: "Quantification of prognostic immune cell markers in colorectal cancer using whole slide imaging tumor maps.", ANAL QUANT CYTOL HISTOL, vol. 32, 2010, pages 333 - 340, XP009167037
ref_type: npl
severity: background
ref_id: - HALAMA, N.; ZOERNIG, I.; SPILLE, A.; WESTPHAL, K.; SCHIRMACHER, P.; JAEGER, D.; GRABE, N.: "Estimation of Immune Cell Densities in Immune Cell Conglomerates: An Approach for High-Throughput Quantification.", PLOS ONE, vol. 4, 2009, pages E7847
ref_type: npl
severity: background
ref_id: - HALAMA ET AL.: "Tumoral immune cell exploitation in colorectal cancer liver metastases can be targeted effectively by anti-CCR5 therapy in cancer patients", CANCER CELL, 2016
ref_type: npl
severity: background
ref_id: - HRISTOV G; KRAMER M; LI J; EL-ANDALOUSSI N; MORA R; DAEFFLER L; ZENTGRAF H; ROMMELAERE J; MARCHINI A: "Through Its Nonstructural Protein NS1, Parvovirus H-1 Induces Apoptosis via Accumulation of Reactive Oxygen Species", J VIROL, vol. 84, 2010, pages 5909 - 5922
ref_type: npl
severity: background
ref_id: - NUESCH JP; LACROIX J; MARCHINI A; ROMMELAERE J: "Molecular pathways: rodent parvoviruses--mechanisms of oncolysis and prospects for clinical cancer treatment", CLIN CANCER RES, vol. 18, 2012, pages 3516 - 3523
ref_type: npl
severity: background
ref_id: - OHSHIMA T; IWAMA M; UENO Y; SUGIYAMA F; NAKAJIMA T; FUKAMIZU A; YAGAMI K: "Induction of apoptosis in vitro and in vivo by H-1 parvovirus infection", THE JOURNAL OF GENERAL VIROLOGY, vol. 79, 1998, pages 3067 - 3071
ref_type: npl
severity: background
ref_id: - RAN Z; RAYET B; ROMMELAERE J; FAISST S: "Parvovirus H-1-induced cell death: influence of intracellular NAD consumption on the regulation of necrosis and apoptosis.", VIRUS RES, vol. 65, 1999, pages 161 - 174
ref_type: npl
severity: background
ref_id: - RAYET B; LOPEZ-GUERRERO JA; ROMMELAERE J; DINSART C: "Induction of programmed cell death by parvovirus H-1 in U937 cells: connection with the tumor necrosis factor alpha signalling pathway", J VIROL, vol. 72, 1998, pages 8893 - 8903
ref_type: npl
severity: background
ref_id: - RUSSELL SJ; PENG KW; BELL JC: "Oncolytic virotherapy.", NAT BIOTECHNOL, vol. 30, 2012, pages 658 - 670, XP055164204, DOI: doi:10.1038/nbt.2287
ref_type: npl
severity: background
ref_id: - UENO Y; HARADA T; ISEKI H; OHSHIMA T; SUGIYAMA F; YAGAMI K: "Propagation of rat parvovirus in thymic lymphoma cell line C58(NT)d and subsequent appearance of a resistant cell clone after lytic infection", J VIROL, vol. 75, 2001, pages 3965 - 3970
ref_type: npl
severity: background
ref_id: WO2016009017A1
ref_type: patent
severity: background
ref_id: WO2010139401A1
ref_type: patent
severity: background
ref_id: WO2015010782A1
ref_type: patent
severity: background
ref_id: WO2009083232A1
ref_type: patent
severity: background
ref_id: - KARISHMA RAJANI ET AL: "Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses", MOLECULAR THERAPY, vol. 24, no. 1, 1 January 2016 (2016-01-01), US, pages 166 - 174, XP055375845, ISSN: 1525-0016, DOI: 10.1038/mt.2015.156
ref_type: npl
severity: background
ref_id: - NORMAN WOLLER ET AL: "Oncolytic Viruses As Anticancer Vaccies", FRONTIERS IN ONCOLOGY, vol. 4, 21 July 2014 (2014-07-21), pages 188, XP055282709
ref_type: npl
severity: background
ref_id: - J. C. PAGLINO ET AL: "LuIII Parvovirus Selectively and Efficiently Targets, Replicates in, and Kills Human Glioma Cells", JOURNAL OF VIROLOGY, vol. 86, no. 13, 1 July 2012 (2012-07-01), pages 7280 - 7291, XP055206096, ISSN: 0022-538X, DOI: 10.1128/JVI.00227-12
ref_type: npl
severity: background
ref_id: - SUZANNE L TOPALIAN ET AL: "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", THE NEW ENGLAND JOURNAL OF MEDICINE, 28 June 2012 (2012-06-28), United States, pages 2443 - 2454, XP055098235, Retrieved from the Internet <URL:http://search.proquest.com/docview/1022620071> DOI: 10.1056/NEJMoa1200690
ref_type: npl
severity: background
ref_id: WO2009083232
ref_type: patent
severity: background
ref_id: WO2010139401
ref_type: patent
severity: obviousness
ref_id: WO2015010782
ref_type: patent
severity: background
ref_id: WO2016009017
ref_type: patent
severity: novelty_destroying
ref_id: - KARISHMA RAJANI ET AL, "Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses", MOLECULAR THERAPY, US, (20160101), vol. 24, no. 1, doi:10.1038/mt.2015.156, ISSN 1525-0016, pages 166 - 174, XP055375845 [X] 1,3,6-9,11 * abstract * * page  167, column  1, paragraph  2 * * page  170, column  1, paragraph  3  - column  2, paragraph  1 * * page  172, column  2, paragraph  4  - page  173, column  2, paragraph  1; figure 1 * [Y] 2,5,10,14
ref_type: npl
severity: novelty_destroying
ref_id: - NORMAN WOLLER ET AL, "Oncolytic Viruses As Anticancer Vaccies", FRONTIERS IN ONCOLOGY, (20140721), vol. 4, page 188, XP055282709 [Y] 2,10,14 * abstract * * page  8, column  2, paragraph  3  - page  9, column  2, paragraph  1; figure 1 *
ref_type: npl
severity: obviousness
ref_id: - J. C. PAGLINO ET AL, "LuIII Parvovirus Selectively and Efficiently Targets, Replicates in, and Kills Human Glioma Cells", JOURNAL OF VIROLOGY, (20120701), vol. 86, no. 13, doi:10.1128/JVI.00227-12, ISSN 0022-538X, pages 7280 - 7291, XP055206096 [A] 1-14 * abstract * * page  7288, column  2, paragraph  2  - page  7289, column  1, paragraph  1 *
ref_type: npl
severity: background
ref_id: - Suzanne L Topalian ET AL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", The New England journal of medicine, United States, doi:10.1056/NEJMoa1200690, (20120628), pages 2443 - 2454, URL: http://search.proquest.com/docview/1022620071, XP055098235 [A] 1-14 * abstract *
ref_type: npl
severity: background
Final disposition: pending (2017-10-04)